# A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

> **NCT03913949** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 74 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** APG-2575

## Key facts

- **NCT ID:** NCT03913949
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-03
- **Primary completion:** 2024-10-20
- **Final completion:** 2026-12-31
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03913949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03913949, "A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03913949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*